Halozyme Therapeutics, Inc. (0J2O.L)
USD 61.28
(-2.05%)
USD 61.28
(-2.05%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 299.31 Million USD | 18.18% |
| 2022 | 253.28 Million USD | 194.53% |
| 2021 | 85.99 Million USD | 7.53% |
| 2020 | 79.97 Million USD | -63.33% |
| 2019 | 218.05 Million USD | 3.32% |
| 2018 | 211.05 Million USD | 3.23% |
| 2017 | 204.45 Million USD | 3.95% |
| 2016 | 196.69 Million USD | 47.6% |
| 2015 | 133.26 Million USD | 15.24% |
| 2014 | 115.63 Million USD | -10.35% |
| 2013 | 128.98 Million USD | 35.98% |
| 2012 | 94.85 Million USD | 25.36% |
| 2011 | 75.66 Million USD | 13.11% |
| 2010 | 66.89 Million USD | -6.85% |
| 2009 | 71.81 Million USD | 22.0% |
| 2008 | 58.86 Million USD | 85.64% |
| 2007 | 31.7 Million USD | 96.61% |
| 2006 | 16.12 Million USD | 18.27% |
| 2005 | 13.63 Million USD | 50.05% |
| 2004 | 9.08 Million USD | 11582.09% |
| 2003 | 77.79 Thousand USD | 0.4% |
| 2002 | 77.48 Thousand USD | 59.64% |
| 2001 | 48.53 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 56.74 Million USD | 4.62% |
| 2024 Q1 | 54.24 Million USD | -29.28% |
| 2024 Q3 | 77.46 Million USD | 36.5% |
| 2023 FY | 299.31 Million USD | 18.18% |
| 2023 Q1 | 73.17 Million USD | 12.8% |
| 2023 Q2 | 76.51 Million USD | 4.56% |
| 2023 Q4 | 76.7 Million USD | 5.18% |
| 2023 Q3 | 72.93 Million USD | -4.68% |
| 2022 Q4 | 64.86 Million USD | -17.22% |
| 2022 Q3 | 78.36 Million USD | -7.11% |
| 2022 Q1 | 25.68 Million USD | 7.56% |
| 2022 Q2 | 84.36 Million USD | 228.42% |
| 2022 FY | 253.28 Million USD | 194.53% |
| 2021 Q4 | 23.88 Million USD | 10.28% |
| 2021 Q3 | 21.65 Million USD | 6.2% |
| 2021 Q1 | 20.06 Million USD | 12.7% |
| 2021 Q2 | 20.39 Million USD | 1.6% |
| 2021 FY | 85.99 Million USD | 7.53% |
| 2020 Q3 | 19.44 Million USD | -2.39% |
| 2020 FY | 79.97 Million USD | -63.33% |
| 2020 Q4 | 17.8 Million USD | -8.44% |
| 2020 Q2 | 19.92 Million USD | -12.57% |
| 2020 Q1 | 22.79 Million USD | -66.99% |
| 2019 Q1 | 49.33 Million USD | -9.78% |
| 2019 FY | 218.05 Million USD | 3.32% |
| 2019 Q4 | 69.04 Million USD | 42.54% |
| 2019 Q3 | 48.43 Million USD | -5.49% |
| 2019 Q2 | 51.24 Million USD | 3.88% |
| 2018 Q4 | 54.68 Million USD | 8.49% |
| 2018 FY | 211.05 Million USD | 3.23% |
| 2018 Q1 | 51.53 Million USD | -8.22% |
| 2018 Q2 | 54.43 Million USD | 5.64% |
| 2018 Q3 | 50.4 Million USD | -7.41% |
| 2017 Q3 | 47.32 Million USD | -8.01% |
| 2017 Q4 | 56.14 Million USD | 18.65% |
| 2017 Q1 | 49.55 Million USD | -7.51% |
| 2017 Q2 | 51.44 Million USD | 3.81% |
| 2017 FY | 204.45 Million USD | 3.95% |
| 2016 Q3 | 45.46 Million USD | -2.76% |
| 2016 Q2 | 46.75 Million USD | -8.16% |
| 2016 Q1 | 50.9 Million USD | 32.79% |
| 2016 FY | 196.69 Million USD | 47.6% |
| 2016 Q4 | 53.57 Million USD | 17.85% |
| 2015 Q3 | 37.83 Million USD | 22.02% |
| 2015 Q1 | 26.08 Million USD | -7.12% |
| 2015 Q4 | 38.33 Million USD | 1.32% |
| 2015 FY | 133.26 Million USD | 15.24% |
| 2015 Q2 | 31 Million USD | 18.89% |
| 2014 Q3 | 28.49 Million USD | 3.98% |
| 2014 FY | 115.63 Million USD | -10.35% |
| 2014 Q4 | 28.08 Million USD | -1.44% |
| 2014 Q2 | 27.4 Million USD | -13.47% |
| 2014 Q1 | 31.66 Million USD | 4.57% |
| 2013 Q4 | 30.28 Million USD | -10.47% |
| 2013 Q1 | 29.59 Million USD | 15.83% |
| 2013 FY | 128.98 Million USD | 35.98% |
| 2013 Q2 | 35.29 Million USD | 19.26% |
| 2013 Q3 | 33.82 Million USD | -4.15% |
| 2012 Q3 | 25.13 Million USD | 16.04% |
| 2012 Q1 | 22.5 Million USD | 8.31% |
| 2012 Q2 | 21.66 Million USD | -3.77% |
| 2012 Q4 | 25.54 Million USD | 1.63% |
| 2012 FY | 94.85 Million USD | 25.36% |
| 2011 Q1 | 17.19 Million USD | -16.41% |
| 2011 FY | 75.66 Million USD | 13.11% |
| 2011 Q4 | 20.78 Million USD | 16.9% |
| 2011 Q3 | 17.77 Million USD | -10.73% |
| 2011 Q2 | 19.91 Million USD | 15.84% |
| 2010 Q3 | 15.82 Million USD | 3.54% |
| 2010 Q4 | 20.56 Million USD | 29.98% |
| 2010 FY | 66.89 Million USD | -6.85% |
| 2010 Q1 | 15.22 Million USD | -19.7% |
| 2010 Q2 | 15.28 Million USD | 0.38% |
| 2009 Q4 | 18.96 Million USD | 12.42% |
| 2009 Q2 | 18.46 Million USD | 5.35% |
| 2009 Q3 | 16.86 Million USD | -8.66% |
| 2009 FY | 71.81 Million USD | 22.0% |
| 2009 Q1 | 17.52 Million USD | -12.2% |
| 2008 Q4 | 19.96 Million USD | 47.52% |
| 2008 Q2 | 12.77 Million USD | 1.35% |
| 2008 Q1 | 12.6 Million USD | 12.15% |
| 2008 FY | 58.86 Million USD | 85.64% |
| 2008 Q3 | 13.53 Million USD | 5.95% |
| 2007 Q4 | 11.23 Million USD | 22.22% |
| 2007 Q3 | 9.19 Million USD | 42.18% |
| 2007 Q2 | 6.46 Million USD | 34.3% |
| 2007 Q1 | 4.81 Million USD | -4.74% |
| 2007 FY | 31.7 Million USD | 96.61% |
| 2006 Q2 | 3.51 Million USD | -5.51% |
| 2006 Q1 | 3.72 Million USD | 3.02% |
| 2006 FY | 16.12 Million USD | 18.27% |
| 2006 Q4 | 5.05 Million USD | 31.87% |
| 2006 Q3 | 3.83 Million USD | 8.93% |
| 2005 Q3 | 3.78 Million USD | 27.3% |
| 2005 Q4 | 3.61 Million USD | -4.42% |
| 2005 Q1 | 3.27 Million USD | 29.39% |
| 2005 Q2 | 2.97 Million USD | -9.19% |
| 2005 FY | 13.63 Million USD | 50.05% |
| 2004 Q2 | 2.08 Million USD | 73.01% |
| 2004 Q3 | 3.26 Million USD | 56.2% |
| 2004 Q1 | 1.2 Million USD | 2705.06% |
| 2004 FY | 9.08 Million USD | 11582.09% |
| 2004 Q4 | 2.52 Million USD | -22.53% |
| 2003 Q4 | 43.04 Thousand USD | 229.98% |
| 2003 Q3 | 13.04 Thousand USD | 7.52% |
| 2003 FY | 77.79 Thousand USD | 0.4% |
| 2003 Q1 | 11.07 Thousand USD | -42.93% |
| 2003 Q2 | 12.13 Thousand USD | 9.53% |
| 2002 FY | 77.48 Thousand USD | 59.64% |
| 2002 Q4 | 19.41 Thousand USD | -24.56% |
| 2002 Q1 | 13.71 Thousand USD | 0.0% |
| 2002 Q2 | 18.62 Thousand USD | 35.83% |
| 2002 Q3 | 25.72 Thousand USD | 38.11% |
| 2001 FY | 48.53 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 82.86% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -2365.349% |
| Myriad Genetics, Inc. | 600.1 Million USD | 50.122% |
| Evolus, Inc. | 189.75 Million USD | -57.736% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 61.606% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 85.848% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 26.782% |
| uniQure N.V. | 285.08 Million USD | -4.992% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -436.835% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -8.569% |
| bluebird bio, Inc. | 240.23 Million USD | -24.595% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -517.125% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 83.372% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 18.799% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 30.009% |
| Dynavax Technologies Corporation | 219.14 Million USD | -36.584% |
| Editas Medicine, Inc. | 247.3 Million USD | -21.032% |
| FibroGen, Inc. | 398.11 Million USD | 24.816% |
| Geron Corporation | 70.44 Million USD | -324.92% |
| Blueprint Medicines Corporation | 722.86 Million USD | 58.593% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 85.42% |
| Illumina, Inc. | 3.81 Billion USD | 92.15% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 33.631% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -664.483% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 81.252% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -110.102% |
| Adicet Bio, Inc. | 152.03 Million USD | -96.871% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 78.005% |
| Insmed Incorporated | 949.26 Million USD | 68.468% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 45.733% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 72.524% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -570.11% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 43.419% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.263% |
| Waters Corporation | 943.51 Million USD | 68.276% |
| Zoetis Inc. | 2.76 Billion USD | 89.175% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 97.081% |
| Biogen Inc. | 5.2 Billion USD | 94.249% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -30.889% |
| Nektar Therapeutics | 190.9 Million USD | -56.791% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -196.863% |
| Perrigo Company plc | 1.52 Billion USD | 80.418% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 37.166% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -148.073% |
| Verastem, Inc. | 92.08 Million USD | -225.049% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 93.732% |
| Imunon, Inc. | 21.03 Million USD | -1323.261% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -2051.874% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -10.085% |
| Homology Medicines, Inc. | 9.87 Million USD | -2931.068% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 89.368% |
| OPKO Health, Inc. | 574.68 Million USD | 47.916% |
| Exelixis, Inc. | 1.58 Billion USD | 81.137% |
| TG Therapeutics, Inc. | 198.47 Million USD | -50.809% |
| Incyte Corporation | 1.19 Billion USD | 74.858% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 71.33% |